| Outcome Measures: |
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26, HbA1c is glycosylated hemoglobin. It was measured at Baseline and at Week 26. The analysis was conducted using mixed-effect model with repeated measures (MMRM). The model included HbA1c change from Baseline as the dependent variable; treatment, region, age category, current metformin use, visit week, treatment-by-week interaction, and Baseline HbA1c-by-week interaction as fixed effects; Baseline HbA1c as a continuous covariate; and participant as a random effect. The Baseline value was the last available non-missing value prior to the first dose of the randomized treatment, thus Baseline was Day -1. Change from Baseline is defined as the post-Baseline value minus the Baseline value., Baseline (Day -1) and Week 26 | Secondary: Number of Participants Treated With Once-weekly Albiglutide That Were Able to Discontinue Insulin Lispro at Week 4 and Did Not Meet Prespecified Criteria for Severe, Persistent Hyperglycemia Through Week 26, Participants who did not meet prespecified criteria for severe, persistent hyperglycemia through Week 26 were those participants treated with once-weekly albiglutide that were able to replace prandial insulin without lispro re-introduction through Week 26. Number of participants treated with once-weekly albiglutide that were able to discontinue insulin lispro at Week 4 and did not meet prespecified criteria for severe, persistent hyperglycemia through Week 26 have been presented., Up to Week 26|Percentage of Participants With Severe or Documented Symptomatic Hypoglycemia Through Week 26, Severe hypoglycemia was considered as an event requiring assistance of another person to actively administer carbohydrates, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal was considered sufficient evidence that the event was induced by a low plasma glucose concentration. Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia are accompanied by a measured plasma glucose concentration \<=70 milligrams per deciliters (mg/dL) (\<=3.9 millimoles per liters \[mmol/L\])., Up to Week 26|Change From Baseline in Body Weight at Week 26, Body weight was measured to the nearest 0.1 kilogram on a standard calibrated scale. Participants dressed in light indoor clothes (no coat, jacket, etc.) without shoes and with a voided bladder. The same equipment was used wherever possible. The Baseline value was the last available non-missing value prior to the first dose of the randomized treatment, thus Baseline was Day -1. Change from Baseline is defined as the post-Baseline value minus the Baseline value., Baseline (Day -1) and Week 26|Change From Baseline to Week 26 in Body Weight, Body weight was measured to the nearest 0.1 kilogram on a standard calibrated scale. Participants dressed in light indoor clothes (no coat, jacket, etc.) without shoes and with a voided bladder. The same equipment was used wherever possible. The Baseline value was the last available non-missing value prior to the first dose of the randomized treatment, thus Baseline was Day -1. Change from Baseline is defined as the post-Baseline value minus the Baseline value. Change from Baseline to Week 26 in body weight are presented. FA Population was analyzed. Only those participants available at the specified time points were analyzed represented by n=X,X in the category titles., Baseline (Day -1) to Week 26|Total Daily Insulin Dose at Week 26, Insulin dose at Week 26 was defined as the prescribed insulin dose at Week 25. Based on MMRM model, prescribed total daily basal insulin dose was equal to Baseline prescribed total daily basal insulin dose + treatment + Baseline HbA1c category + region + age category + current use of metformin + visit week + treatment-by-visit week interaction + Baseline prescribed total daily basal insulin dose-by-visit week interaction. Total daily insulin dose at Week 26 is presented. Only those participants available at the specified time points were analyzed., Week 26|Change From Baseline to Week 26 in HbA1c, HbA1c is glycosylated hemoglobin and was measured up to Week 26. The Baseline value was the last available non-missing value prior to the first dose of the randomized treatment, thus Baseline was Day -1. Change from Baseline is defined as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed represented by n=X,X in the category titles., Baseline to Week 26|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26, FPG was measured at Baseline (Day -1). FPG values for all participants at Week 26 were not collected due to an error in the protocol and were imputed with the fasting serum glucose (FSG) values at this time point. The imputation of the FPG at Week 26 from the FSG values was deemed acceptable from the results of the analysis of the correlation between FPG and FSG at the screening visit. The Baseline value was the last available non-missing value prior to the first dose of the randomized treatment, thus Baseline was Day -1. Change from Baseline is defined as the post-Baseline value minus the Baseline value., Baseline and Week 26|Change From Baseline to Week 26 in FPG, FPG was measured at Baseline (Day -1) up to Week 26. FPG values for all participants at Week 26 were not collected due to an error in the protocol and were imputed with the FSG values at this time point. The imputation of the FPG at Week 26 from the FSG values was deemed acceptable from the results of the analysis of the correlation between FPG and FSG at the screening visit. The Baseline value was the last available non-missing value prior to the first dose of the randomized treatment, thus Baseline was Day -1. Change from Baseline is defined as the post-Baseline value minus the Baseline value., Baseline to Week 26|Number of Participants Achieving HbA1c <7.0% at Week 26, HbA1c is glycosylated hemoglobin. Number of participants achieving a HbA1c \<7.0% at Week 26 are presented., Week 26|Number of Participants Achieving HbA1c <7.0% up to Week 26, HbA1c is glycosylated hemoglobin. Number of participants achieving a HbA1c \<7.0% up to Week 26 are presented., Up to Week 26|Number of Participants Achieving a HbA1c <6.5% at Week 26, Number of participants achieving a HbA1c \<6.5% at Week 26 are presented., Week 26|Number of Participants Achieving a HbA1c <6.5% up to Week 26, Number of participants achieving a HbA1c \<6.5% up to Week 26 are presented., Up to Week 26|Number of Participants Who Met Prespecified Criteria for Severe, Persistent Hyperglycemia at Week 26, Meeting prespecified criteria for severe, persistent hyperglycemia was defined operationally as being withdrawn due to lack of efficacy as recorded on the Treatment Discontinuation and Study Conclusion electronic case report form pages. Number of participants who met prespecified criteria for severe, persistent hyperglycemia at Week 26 are presented., Week 26|Number of Participants Meeting Prespecified Criteria for Severe, Persistent Hyperglycemia up to Week 26, Meeting prespecified criteria for severe, persistent hyperglycemia was defined operationally as being withdrawn due to lack of efficacy as recorded on the Treatment Discontinuation and Study Conclusion electronic case report form pages. Number of participants meeting prespecified criteria for severe, persistent hyperglycemia up to Week 26 are presented., Up to Week 26|Total Daily Insulin Dose at Week 4, Week 10 and Week 18, Based on MMRM model, prescribed total daily basal insulin dose was equal to Baseline prescribed total daily basal insulin dose + treatment + Baseline HbA1c category + region + age category + current use of metformin + visit week + treatment-by-visit week interaction + Baseline prescribed total daily basal insulin dose-by-visit week interaction. Total daily insulin dose at Week 4, Week 10 and Week 18 is presented. Only those participants available at the specified time points were analyzed represented by n=X,X in the category titles., Weeks 4, 10, and 18|Total Daily Basal Insulin (Insulin Glargine) at Week 4, 10, 18, and 26 Visits, Based on MMRM model, prescribed total daily basal insulin dose was equal to Baseline prescribed total daily basal insulin dose + treatment + Baseline HbA1c category + region + age category + current use of metformin + visit week + treatment-by-visit week interaction + Baseline prescribed total daily basal insulin dose-by-visit week interaction. Total daily basal insulin (insulin glargine) at Week 4, 10, 18, and 26 visits is presented. Only those participants available at the specified time points were analyzed represented by n=X,X in the category titles., Weeks 4, 10, 18, and 26|Total Daily Bolus Insulin (Insulin Lispro) at Week 4, 10, 18, and 26 Visits, Based on MMRM model, prescribed total daily basal insulin dose was equal to Baseline prescribed total daily basal insulin dose + treatment + Baseline HbA1c category + region + age category + current use of metformin + visit week + treatment-by-visit week interaction + Baseline prescribed total daily basal insulin dose-by-visit week interaction. Total daily bolus insulin (insulin lispro) at Week 4, 10, 18, and 26 visits is presented. Only those participants available at the specified time points were analyzed represented by n=X,X in the category titles., Weeks 4, 10, 18, and 26|Total Number of Weekly Insulin Injections to Achieve Glycemic Control at Baseline/Randomization and Week 4, 10, 18, and 26, Total number of weekly insulin injections (7 days) to achieve glycemic control at Baseline/Randomization and Week 4, 10, 18, and 26 are presented. Only those participants available at the specified time points were analyzed represented by n=X,X in category titles., Baseline (Day -1) and Weeks 4, 10, 18 and 26|Percentage of Participants Achieving HbA1c <7.0% Without Weight Gain at Week 26, Percentage of participants achieving HbA1c \<7.0% without weight gain are presented., Week 26|Percentage of Participants Achieving HbA1c <7.0% Without Severe or Documented Symptomatic Hypoglycemia at Week 26, Percentage of participants achieving HbA1c \<7.0% without severe or documented symptomatic hypoglycemia are presented., Week 26|Percentage of Participants Achieving HbA1c <7.0% Without Weight Gain and Without Severe or Documented Hypoglycemia at Week 26, Percentage of participants achieving HbA1c \<7.0% without weight gain and without severe or documented hypoglycemia are presented., Week 26|Number of Participants With On-therapy Adverse Events (AE) and Serious AE (SAE), and AE Leading to Discontinuation of Randomized Study Medication, AE is any untoward medical occurrence in a participant, temporally associated with use of medicinal product (MP), whether or not considered related to MP. AE can be any unfavorable, unintended sign (also an abnormal laboratory finding), symptom, or disease (new/exacerbated) temporally associated with use of MP. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, or is a congenital anomaly/birth defect or is medically significant or all events of possible drug induced liver injury with hyperbilirubinemia. Safety Population: All participants who received at least 1 dose of randomized study medication. A participant randomized to Albiglutide + Insulin glargine by mistake received Insulin Lispro + Insulin Glargine instead. Since this participant received actual treatment as Insulin Lispro + Insulin Glargine, was summarized as such in Safety Population., Up to Week 26|Number of Participants With Other AE of Special Interest, AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with use of a MP, whether or not considered related to MP. AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with use of MP. AE of special interest included hypoglycemic events, cardiovascular events, gastrointestinal events, injection site reactions, potential systemic allergic reactions, pancreatitis, pancreatic cancer, malignant neoplasms following treatment with insulin, diabetic retinopathy events, appendicitis, liver events, pneumonia, and atrial fibrillation/flutter., Up to Week 26|Percentage of Participants With Events of Hypoglycemia With Confirmed Home Blood Glucose Monitoring and/or Third-party Intervention Through Week 26, Hypoglycemic events with confirmed home plasma glucose monitoring \<3.9 millimoles per Liter and/or requiring third party intervention were severe, documented symptomatic (DS) and asymptomatic hypoglycemic events. Participants with more than one hypoglycemic event are counted in all categories reported. Any severe, documented symptomatic, and asymptomatic hypoglycemic events in 3-month intervals (i.e., from Day 0 to Week 12, \>Week 12 to Week 26) are presented., Up to Week 26|Number of Participants With Hypoglycemic Events (in Total and by Each Category as Defined by the American Diabetes Association Criteria), The American Diabetes Association has categorized hypoglycemic events as follows: Severe, documented symptomatic, asymptomatic, probably symptomatic and pseudohypoglycemia. Number of participants with hypoglycemic events in total are also presented., Up to Week 26|Number of Participants With Daytime and Nocturnal Hypoglycemia, Daytime hypoglycemia was defined as hypoglycemic events with an onset between 06:00 hours and 00:00 hours (inclusive), and nocturnal hypoglycemia (in total and by category), defined as hypoglycemic events with an onset between 00:01 hours and 05:59 hours (inclusive). Number of participants with daytime and nocturnal hypoglycemia (in total and by category) are presented., Up to Week 26|Number of Participants With Hypoglycemia With Blood Glucose <56 Milligrams Per Deciliter (mg/dL) (<3.1 Millimoles Per Liter [mmol/L]), Regardless of Symptoms, Number of participants with hypoglycemia with blood glucose \<56 mg/dL (\<3.1 mmol/L), regardless of symptoms are presented., Up to Week 26|Number of Participants With Hematology Values of Clinical Concern, Hematology parameters included basophils, eosinophils, hematocrit, hemoglobin, lymphocytes, monocytes, neutrophils, neutrophil bands, platelets, red blood cell (RBC) count, segmented neutrophils and white blood cell (WBC) count. The potential clinical concern values were: Hematocrit \>0.05 below lower limit of normal (LLN) and \>0.04 above upper limit of normal (ULN), hemoglobin: \>20 grams cells per Liter (g/L) below LLN and \>10 g/L above ULN, lymphocytes: \<0.5 x LLN, neutrophils: \<1 giga cells per liter (GI/L), platelets: \<80 GI/L and \>500 GI/L, segmented neutrophils: \<0.5 x LLN, RBC count: \>1 GI/L below LLN and \>5 GI/L above ULN and none for basophils, eosinophils, monocytes, neutrophil bands and RBC count. Only those parameters for which at least one value of potential clinical concern was reported are summarized., Up to 30 weeks|Number of Participants With Clinical Chemistry Values of Clinical Concern, Clinical chemistry parameters and their potential clinical concern values were: albumin (\>5 g/L above ULN or below LLN), alkaline phosphatase(\>3 x ULN), alanine aminotransferase (\>3 x ULN), aspartate aminotransferase (\>3 x ULN), carbon dioxide content (\<16 millimoles per Liter \[mmol/L\] and \> 40 mmol/L), blood urea nitrogen (\>2 x ULN), calcium (\<1.8 mmol/L and \>3.0 mmol/L), chloride (none), creatinine (\>159 micromoles/Liter), direct bilirubin (\>1.35 x ULN), gamma glutamyl transferase (\>3 x ULN), glucose (fasting) (\<3 mmol/L and \>22 mmol/L), magnesium (\<0.411 mmol/L and \>1.644 mmol/L), phosphate (\>0.323 mmol/L above ULN or below LLN), potassium (\>0.5 mmol/L below LLN and \>1.0 mmol/L above ULN), sodium (\>5 mmol/L above ULN or below LLN), triglycerides (\> 9.04 mmol/L), total bilirubin (\>1.5 x ULN), total protein (\>15 g/L above ULN or below LLN) and uric acid (\>654 umol/L). Only those parameters for which at least one value of potential clinical concern was reported are summarized., Up to 30 weeks|Mean Urine Albumin/Creatinine Ratio at Week 0 and Week 26, Urine samples were collected for analysis of albumin/creatinine ratio. Only those participants available at the specified time points were analyzed represented by n=X,X in the category titles. Mean urine albumin/creatinine ratio at Week 0 and Week 26 are presented., Week 0 and Week 26|Mean Albumin at Week 0 and Week 26, Urine samples were collected for analysis of albumin. Only those participants available at the specified time points were analyzed represented by n=X,X in the category titles. Mean albumin at Week 0 and Week 26 are presented., Week 0 and Week 26|Mean Creatinine at Week 0 and Week 26, Urine samples were collected for analysis of creatinine. Only those participants available at the specified time points were analyzed represented by n=X,X in the category titles. Mean creatinine at Week 0 and Week 26 are presented., Week 0 and Week 26|Mean Specific Gravity at Week 0 and Week 26, Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. A urinary specific gravity measurement is a routine part of urinalysis. Only those participants available at the specified time points were analyzed represented by n=X,X in the category titles., Week 0 and Week 26|Number of Participants With Different Values of Potential of Hydrogen (pH) at Week 0 and Week 26, Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Safety Population was analyzed. Only those participants available at the specified time points were analyzed represented by n=X,X in the category titles., Week 0 and Week 26|Number of Participants With Different Number of Erythrocytes in Urine at Week 0 and Week 26, Urine samples were collected for analysis of erythrocyte count. Only those participants available at the specified time points were analyzed represented by n=X,X in the category titles. Number of participants with different number of erythrocytes in urine at Week 0 and Week 26 are presented., Week 0 and Week 26|Number of Participants With Different Number of Leukocytes in Urine at Week 0 and Week 26, Urine samples were collected for analysis of leukocyte count. Only those participants available at the specified time points were analyzed represented by n=X,X in the category titles. Number of participants with different number of leukocytes in urine at Week 0 and Week 26 are presented., Week 0 and Week 26|Change From Baseline in Total Cholesterol (TC), Low-density Lipoprotein Cholesterol (LDL-c), High Density Lipoprotein (HDL-c), Triglycerides (TG) and Free Fatty Acids (FFA) at Week 10 and Week 26, Lipid parameters included TC, LDL-c, HDL-c, TG and FFA. The Baseline value was the last available non-missing value prior to the first dose of the randomized treatment, thus Baseline was Day -1. Change from Baseline is defined as the post-Baseline value minus the Baseline value. LDL-c and FFA were collected as part of the lipid panel and results were reviewed by investigators for individual participants. Change from Baseline at Week 10 and Week 26 was not assessed for these parameters. Analysis of these parameters was not a specific study objective and would not have any impact on study conclusions. Only those parameters with data values have been presented. Only those participants available at the specified time points were analyzed represented by n=X,X in the category titles., Baseline, Week 10 and Week 26|Number of Participants With Vital Signs of Clinical Concern, Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate values. Assessment of vitals were performed with the participant in a semi recumbent or seated position having rested in this position for at least 5 minutes before each reading. The potential clinical concern values were: SBP: \<100 millimeters of mercury (mmHg) and \>170 mmHg, DBP: \<50 mmHg and \>110 mmHg and pulse rate: \<50 beats per minute (bpm) and \> 120 bpm. Number of participants with vital signs of clinical concern are presented., Up to 30 weeks|Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Parameters, A single 12-lead ECG recordings were performed in a participant in semi recumbent position for 10 to 15 minutes before obtaining the ECG. Any clinically significant favorable and unfavorable findings are reported., Up to 30 weeks
|
| Locations: |
GSK Investigational Site, Searcy, Arkansas, 72143, United States|GSK Investigational Site, Huntington Beach, California, 92648, United States|GSK Investigational Site, Long Beach, California, 90807, United States|GSK Investigational Site, Los Angeles, California, 90017, United States|GSK Investigational Site, Tustin, California, 92780, United States|GSK Investigational Site, West Hills, California, 91307, United States|GSK Investigational Site, Colorado Springs, Colorado, 80909, United States|GSK Investigational Site, Brooksville, Florida, 34601, United States|GSK Investigational Site, Clearwater, Florida, 33765, United States|GSK Investigational Site, Hialeah, Florida, 33012, United States|GSK Investigational Site, Miami, Florida, 33156, United States|GSK Investigational Site, Orlando, Florida, 32825, United States|GSK Investigational Site, Pembroke Pines, Florida, 33027, United States|GSK Investigational Site, Tampa, Florida, 33634, United States|GSK Investigational Site, West Palm Beach, Florida, 33401, United States|GSK Investigational Site, Chicago, Illinois, 60612, United States|GSK Investigational Site, Paducah, Kentucky, 42003, United States|GSK Investigational Site, Lake Charles, Louisiana, 70601, United States|GSK Investigational Site, Shreveport, Louisiana, 71105, United States|GSK Investigational Site, Kalamazoo, Michigan, 49009, United States|GSK Investigational Site, Springfield, Missouri, 65807, United States|GSK Investigational Site, Las Vegas, Nevada, 89119, United States|GSK Investigational Site, Staten Island, New York, 10301, United States|GSK Investigational Site, Shelby, North Carolina, 28150, United States|GSK Investigational Site, Wilmington, North Carolina, 28401, United States|GSK Investigational Site, Columbus, Ohio, 43213, United States|GSK Investigational Site, Dayton, Ohio, 45439, United States|GSK Investigational Site, Kettering, Ohio, 45429, United States|GSK Investigational Site, Austin, Texas, 78749, United States|GSK Investigational Site, Austin, Texas, 78756, United States|GSK Investigational Site, Dallas, Texas, 75230, United States|GSK Investigational Site, Houston, Texas, 77058, United States|GSK Investigational Site, Houston, Texas, 77099, United States|GSK Investigational Site, Pharr, Texas, 78577, United States|GSK Investigational Site, Round Rock, Texas, 78681, United States|GSK Investigational Site, Sugar Land, Texas, 77479, United States|GSK Investigational Site, Hampton, Virginia, 23666, United States|GSK Investigational Site, Renton, Washington, 98057, United States|GSK Investigational Site, Tacoma, Washington, 98405, United States|GSK Investigational Site, Fortaleza - CE, Ceará, 60430-350, Brazil|GSK Investigational Site, Fortaleza, Ceará, 60115-282, Brazil|GSK Investigational Site, Goiânia, Goiás, 74110-010, Brazil|GSK Investigational Site, Uberlandia, Minas Gerais, 38411-186, Brazil|GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, 90035-170, Brazil|GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, 90035001, Brazil|GSK Investigational Site, Campinas, São Paulo, 13010-001, Brazil|GSK Investigational Site, Marília, São Paulo, 17519-000, Brazil|GSK Investigational Site, Pará, 66073-000, Brazil|GSK Investigational Site, São Paulo, 01223-001, Brazil|GSK Investigational Site, São Paulo, 04038-002, Brazil|GSK Investigational Site, Penticton, British Columbia, V2A 5C8, Canada|GSK Investigational Site, Brampton, Ontario, L6S 0C9, Canada|GSK Investigational Site, Oakville, Ontario, L6M 1M1, Canada|GSK Investigational Site, Thornhill, Ontario, L4J 8L7, Canada|GSK Investigational Site, Toronto, Ontario, M4G 3E8, Canada|GSK Investigational Site, Saint Laurent, Quebec, H4T 1Z9, Canada|GSK Investigational Site, Corbeil-Essonnes, 91106, France|GSK Investigational Site, Nantes Cedex 1, 44093, France|GSK Investigational Site, Valenciennes, 59322, France|GSK Investigational Site, Vandoeuvre les Nancy, 54501, France|GSK Investigational Site, Venissieux, 69200, France|GSK Investigational Site, Bad Mergentheim, Baden-Wuerttemberg, 97980, Germany|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, 69115, Germany|GSK Investigational Site, Wangen, Baden-Wuerttemberg, 88239, Germany|GSK Investigational Site, Aschaffenburg, Bayern, 63739, Germany|GSK Investigational Site, Sulzbach-Rosenberg, Bayern, 92237, Germany|GSK Investigational Site, Asslar, Hessen, 35614, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, 19059, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, 45355, Germany|GSK Investigational Site, Ludwigshafen am Rhein, Rheinland-Pfalz, 67059, Germany|GSK Investigational Site, Rhaunen, Rheinland-Pfalz, 55624, Germany|GSK Investigational Site, Saarlouis, Saarland, 66740, Germany|GSK Investigational Site, Sankt Ingbert, Saarland, 66386, Germany|GSK Investigational Site, Dresden, Sachsen, 01307, Germany|GSK Investigational Site, Pirna, Sachsen, 01796, Germany|GSK Investigational Site, Berlin, 10115, Germany|GSK Investigational Site, Baja, 6500, Hungary|GSK Investigational Site, Balatonfured, 8230, Hungary|GSK Investigational Site, Budapest, 1036, Hungary|GSK Investigational Site, Budapest, 1158, Hungary|GSK Investigational Site, Budaörs, 2040, Hungary|GSK Investigational Site, Debrecen, 4031, Hungary|GSK Investigational Site, Pecs, 7643, Hungary|GSK Investigational Site, Zalaegerszeg, 8900, Hungary|GSK Investigational Site, Napoli, Campania, 80131, Italy|GSK Investigational Site, Bologna, Emilia-Romagna, 40138, Italy|GSK Investigational Site, Roma, Lazio, 00128, Italy|GSK Investigational Site, Milano, Lombardia, 20122, Italy|GSK Investigational Site, Milano, Lombardia, 20132, Italy|GSK Investigational Site, Pavia, Lombardia, 27100, Italy|GSK Investigational Site, Gyeonggido, 420-717, Korea, Republic of|GSK Investigational Site, Seoul, 135-710, Korea, Republic of|GSK Investigational Site, Pachuca, Hidalgo, 42084, Mexico|GSK Investigational Site, Guadalajara, Jalisco, 44570, Mexico|GSK Investigational Site, Guadalajara, Jalisco, 44657, Mexico|GSK Investigational Site, Guadalajara, Jalisco, 44670, Mexico|GSK Investigational Site, Monterrey NL, Nuevo León, 64718, Mexico|GSK Investigational Site, Monterrey, Nuevo León, 64020, Mexico|GSK Investigational Site, Monterrey, Nuevo León, 64460, Mexico|GSK Investigational Site, Merida, Yucatán, 97070, Mexico|GSK Investigational Site, Aguascalientes, 20129, Mexico|GSK Investigational Site, Aguascalientes, 20230, Mexico|GSK Investigational Site, Chihuahua, 31217, Mexico|GSK Investigational Site, Durango, 34000, Mexico|GSK Investigational Site, Durango, 34080, Mexico|GSK Investigational Site, Guadalajara, 44600, Mexico|GSK Investigational Site, Mexico City, 03300, Mexico|GSK Investigational Site, Mexico, 07760, Mexico|GSK Investigational Site, Mexico, 14000, Mexico|GSK Investigational Site, Veracruz, 91020, Mexico|GSK Investigational Site, Davao City, 8000, Philippines|GSK Investigational Site, Manila, 1000, Philippines|GSK Investigational Site, Marikina City, 1810, Philippines|GSK Investigational Site, Quezon City, 2000, Philippines|GSK Investigational Site, Bialystok, 15-435, Poland|GSK Investigational Site, Kamieniec Zabkowicki, 57-230, Poland|GSK Investigational Site, Lodz, 90-132, Poland|GSK Investigational Site, Oswiecim, 32-600, Poland|GSK Investigational Site, Pulawy, 24-100, Poland|GSK Investigational Site, Radom, 26-610, Poland|GSK Investigational Site, Ruda Slaska, 41-709, Poland|GSK Investigational Site, Zamosc, 22-400, Poland|GSK Investigational Site, Bloemfontein, Free State, 9301, South Africa|GSK Investigational Site, Johannesburg, Gauteng, 1685, South Africa|GSK Investigational Site, Johannesburg, Gauteng, 2013, South Africa|GSK Investigational Site, Durban, KwaZulu- Natal, 4067, South Africa|GSK Investigational Site, Johannesburg, 2193, South Africa|GSK Investigational Site, Krugersdorp, 1724, South Africa|GSK Investigational Site, Worcester, 6850, South Africa|GSK Investigational Site, Alcala de Henares, 28805, Spain|GSK Investigational Site, Alzira/Valencia, 46600, Spain|GSK Investigational Site, Badalona, 08916, Spain|GSK Investigational Site, Barakaldo (Vizcaya), 48903, Spain|GSK Investigational Site, Barcelona, 08036, Spain|GSK Investigational Site, Barcelona, 8041, Spain|GSK Investigational Site, Ferrol. La Coruña, 15405, Spain|GSK Investigational Site, Granada, 18012, Spain|GSK Investigational Site, Granada, 18014, Spain|GSK Investigational Site, La Coruña, 15006, Spain|GSK Investigational Site, León, 24071, Spain|GSK Investigational Site, Lleida, 25198, Spain|GSK Investigational Site, Madrid, 28006, Spain|GSK Investigational Site, Madrid, 28046, Spain|GSK Investigational Site, Majadahonda, 28220, Spain|GSK Investigational Site, Malaga, 29010, Spain|GSK Investigational Site, Merida, 6800, Spain|GSK Investigational Site, Málaga, 29010, Spain|GSK Investigational Site, Palma de Mallorca, 07120, Spain|GSK Investigational Site, Palma de Mallorca, 07198, Spain|GSK Investigational Site, Pozuelo De Alarcón/Madrid, 28223, Spain|GSK Investigational Site, Santiago de Compostela, 15706, Spain|GSK Investigational Site, Valencia, 46014, Spain|GSK Investigational Site, Valencia, 46026, Spain|GSK Investigational Site, Welwyn Garden City, Hertfordshire, AL7 4HQ, United Kingdom|GSK Investigational Site, Bath, Somerset, BA1 3NG, United Kingdom|GSK Investigational Site, Hull, HU3 2JZ, United Kingdom|GSK Investigational Site, Lancashire, BL9 7TD, United Kingdom|GSK Investigational Site, Sidcup, DA14 6LT, United Kingdom
|
